Transforming a family owned generics business to a mission-driven company, fully dedicated to delivering medicines for small, underserved or rare disease populations
To company website
-webp.webp)
overview
Essential Pharma is a Speciality Pharma platform supplying essential medicines to patients in need.
Since the investment, Gyrus has repositioned the business from a UK-focused generics family business to a global provider of innovative and established medicines.
4 Foundations
Ensures availability of critical treatments for all patients, including those in underserved or remote areas, through the supply of complex low-volume medicines at risk of discontinuation
Lean supply chain optimising inventory, minimising waste, and mitigating disruptions in distributing critical healthcare products, crucial during periods of heightened demand or supply chain difficulties
Diverse portfolio of 400+ SKUs driven by underlying demographic trends and protected by regulatory barriers
Repositioned the business from low-volume generics to specialty pharma - commercialising novel treatments for Rare Disease indications
Our investment story
- Gyrus leveraged its pharma sector expertise to position itself as the best partner for the founder to transition the business to institutional ownership
- Successfully transformed the organisation from a family-run business to a global, professionalised organisation selling across >70 countries
- Developed and executed a focused M&A strategy resulting in the deployment of £250m across 10 product acquisitions creating a geographically diversified, specialty pharma business underpinning future growth
- Created a rare diseases platform with products treating Cystic Fibrosis and a late stage development program for a rare paediatric oncology indication
- Appointed an industry-leading management team with a proven track-record in commercialising Rare Disease products
- In 2024, closed a €700m continuation vehicle, to provide a pathway to execute on the Rare Disease strategy and continued expansion of the established medicines portfolio
Outcome
Today, Essential Pharma is uniquely positioned as a Rare Disease innovator underpinned by a resilient established medicines business
“Gyrus brought the relevant sector expertise and deep industry network required to transform Essential Pharma into a global Specialty Pharma platform. They have been a collaborative partner and consistently ensured Management have the adequate resources to execute on their vision and strategy”
Lee Morley
Chairman